The composition of endogenous T cells used in manufacturing the CAR product, including the CD4:CD8 ratio and presence of central memory and stem cell memory T cells, has been shown to affect CAR T expansion, anti-tumor activity, and clinical response in myeloma and other B cell malignancies (77–79). The gene discussed is CD8A; the disease is plasma cell myeloma.